| Identification | Back Directory | [Name]
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2alpha,5alpha,6beta(S*)]]- | [CAS]
42057-22-7 | [Synonyms]
Baypen
Baycipen
Einecs 255-640-5
Monosodium mezlocillin
(2S,5β)-3,3-Dimethyl-6α-[[(R)-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2β-carboxylic acid sodium salt
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((2R)-(((3-(methylsulfonyl)-2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-7-oxo-, monosodium salt, (2S,5R,6R)-
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[(2R)-2-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-2-phenylacetyl]amino]-7-oxo-, sodium salt (1:1), (2S,5R,6R)-
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2alpha,5alpha,6beta(S*)]]-
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((((3-(methylsulfonyl)-2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-7-oxo-, monosodium salt, (2S-(2alpha,5alpha,6beta(S*)))-
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid,3,3-dimethyl-6-[[[[[3-(methylsulfonyl)-2-oxo-1-imChemicalbookidazolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-,monosodiumsalt,[2S-[2alpha,5alpha,6beta(S*)]]- USP/EP/BP | [EINECS(EC#)]
255-640-5 | [Molecular Formula]
C21H24N5NaO8S2 | [MDL Number]
MFCD07793332 | [MOL File]
42057-22-7.mol | [Molecular Weight]
561.564 |
| Hazard Information | Back Directory | [Uses]
Mezlocillin Sodium is an antibacterial agent. Penicillin antibiotic effective against gram negative and gram positive bacteria. | [Definition]
ChEBI: Mezlocillin sodium is an organic sodium salt. It contains a mezlocillin(1-). | [in vivo]
Mezlocillin (subcutaneous injection; 1.7-5.7 mg/kg; twice daily; 7 d) treatment in vivo suppresses the IgM and IgG responses and the delayed-type hypersensitivity reaction, observes the loss of hair, and inhibits lymphocyte proliferation of animals treated with all doses[1]. | Animal Model: | Male Balb/c mice[1] | | Dosage: | 1.7, 4.3, and 5.7 mg/kg | | Administration: | Subcutaneous injection; 1.7, 4.3, and 5.7 mg/kg; twice daily; 7 days | | Result: | Suppressed the IgM and IgG responses and the delayed-type hypersensitivity reaction treated with all doses.
Observed a loss of hair in the majority of animals treated with all doses.
Inhibited lymphocyte proliferation of spleen-cell cultures from animals. |
| [IC 50]
β-lactam |
| Spectrum Detail | Back Directory | [Spectrum Detail]
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2alpha,5alpha,6beta(S*)]]-(42057-22-7)MS
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2alpha,5alpha,6beta(S*)]]-(42057-22-7)1HNMR
|
|
|